Quarterly ResultMay 13, 2026, 04:18 PM
Macrogenics Q1 Net Loss $(36.8)M; Revenue $20.8M, up 57%
AI Summary
Macrogenics reported a reduced net loss of $(36.8) million for the first quarter of 2026, an improvement from $(41.0) million in the prior year. Total revenues increased by 57% to $20.8 million, driven by strong growth in contract manufacturing and royalty revenue, despite a decrease in collaborative agreements. The company also saw a decrease in research and development expenses and an increase in cash and cash equivalents, indicating improved operational cash flow.
Key Highlights
- Net loss decreased to $(36.8) million for Q1 2026 from $(41.0) million for Q1 2025.
- Total revenues increased 57% to $20.8 million for Q1 2026 from $13.2 million for Q1 2025.
- Contract manufacturing revenue rose to $14.1 million in Q1 2026 from $6.2 million in Q1 2025.
- Royalty revenue increased to $6.2 million in Q1 2026 from $0.4 million in Q1 2025.
- Research and development expenses decreased to $35.0 million in Q1 2026 from $39.7 million in Q1 2025.
- Cash and cash equivalents increased to $66.5 million at March 31, 2026, from $57.2 million at December 31, 2025.
- Net cash used in operating activities improved to $(35.8) million in Q1 2026 from $(46.9) million in Q1 2025.
- Current deferred revenue significantly increased to $68.0 million at March 31, 2026, from $10.9 million at December 31, 2025.